Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 2/2019

04.05.2019 | Solid Tumor

Comparison and screening of different risk assessment models for deep vein thrombosis in patients with solid tumors

verfasst von: Meng-meng Wang, Xiao-juan Qin, Xiao-xiao He, Meng-jun Qiu, Gang Peng, Sheng-li Yang

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

To increase the detection rate of deep vein thrombosis (DVT) and to compare the predictive value of four different risk assessment scales (Caprini, Autar, Pauda, and Khorana scales) for DVT in patients with solid tumors by the receiver operating curve (ROC). A total of 361 patients with all kinds of malignant solid tumors, who accepted anti-tumor therapy in the cancer center between March 3, 2015 to April 13, 2018, were assigned to a group of 230 cases diagnosed with DVT and a control group of 131 cases without DVT. Data were recorded and summarized, and the predictive value of the above four risk assessment scales for DVT in solid tumor patients was compared based on the area under the ROC curve (AUC). The AUC values determined for the Caprini, Autar, Pauda, and Khorana scales were (0.631 ± 0.030), (0.686 ± 0.028), (0.654 ± 0.029), and (0.599 ± 0.032), respectively; maximum sensitivity, specificity, and Youden index were 80.9% for Khorana, 86.3% for Caprini, and 29.6% for Autar scale, respectively. We found no statistically significant differences in the AUC values between Autar and Caprini, Autar and Khorana, as well as Khorana and Pauda (p > 0.05). However, the AUC differences between Autar and Pauda, Caprini and Khorana, as well as Caprini and Pauda were statistically significant (p < 0.05). All four risk assessment models showed some value in the risk prediction of DVT in patients with solid tumors, but every model also exhibited its own restrictions; maximum sensitivity, specificity, and Youden index were 80.9% for Khorana, 86.3% for Caprini, and 29.6% for Autar scale, respectively. We confirmed that the detection rate can be improved by modifying the BMI cut-off value of the scale or by combining appropriate scales.
Literatur
1.
Zurück zum Zitat Fowkes FJI, Price JF, Fowkes FGR (2003) Incidence of diagnosed deep vein thrombosis in the general population: Systematic review. Eur J Vasc Endovasc Surg 25(1):1–5CrossRefPubMed Fowkes FJI, Price JF, Fowkes FGR (2003) Incidence of diagnosed deep vein thrombosis in the general population: Systematic review. Eur J Vasc Endovasc Surg 25(1):1–5CrossRefPubMed
4.
Zurück zum Zitat Riess H, Habbel P, Juhling A (2016) Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancer. World J Gastrointest Oncol 8(3):258–270CrossRefPubMedPubMedCentral Riess H, Habbel P, Juhling A (2016) Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancer. World J Gastrointest Oncol 8(3):258–270CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Di Nisio M et al (2011) Arterial thrombosis in ambulatory cancer patients treated with chemotherapy. Thromb Res 127(4):382–383CrossRefPubMed Di Nisio M et al (2011) Arterial thrombosis in ambulatory cancer patients treated with chemotherapy. Thromb Res 127(4):382–383CrossRefPubMed
6.
Zurück zum Zitat Falanga A, Marchetti M, Vignoli A (2013) Coagulation and cancer: biological and clinical aspects. J Thromb Haemost 11(2):223–233CrossRefPubMed Falanga A, Marchetti M, Vignoli A (2013) Coagulation and cancer: biological and clinical aspects. J Thromb Haemost 11(2):223–233CrossRefPubMed
7.
Zurück zum Zitat Timp JF et al (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712–1723CrossRefPubMed Timp JF et al (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712–1723CrossRefPubMed
9.
Zurück zum Zitat Ay C, Pabinger I, Cohen AA (2016) Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost 117:219–230PubMed Ay C, Pabinger I, Cohen AA (2016) Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost 117:219–230PubMed
10.
Zurück zum Zitat Falanga A, Marchetti M, Russo L (2015) The mechanisms of cancer-associated thrombosis. Thromb Haemost 135:S8–S11 Falanga A, Marchetti M, Russo L (2015) The mechanisms of cancer-associated thrombosis. Thromb Haemost 135:S8–S11
11.
Zurück zum Zitat Autar R (2003) The management of deep vein thrombosis: the Autar DVT risk assessment scale re-visited. J Orthop Nurs 7(3):114–124CrossRef Autar R (2003) The management of deep vein thrombosis: the Autar DVT risk assessment scale re-visited. J Orthop Nurs 7(3):114–124CrossRef
12.
13.
Zurück zum Zitat Verso M et al (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 7(3):291–292CrossRefPubMed Verso M et al (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 7(3):291–292CrossRefPubMed
14.
Zurück zum Zitat Bahl V et al (2010) A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg 251(2):344–350CrossRefPubMed Bahl V et al (2010) A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg 251(2):344–350CrossRefPubMed
15.
Zurück zum Zitat Barbar S et al (2010) A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Pauda Prediction Score. J Thromb Haemost 8(11):2450–2457CrossRefPubMed Barbar S et al (2010) A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Pauda Prediction Score. J Thromb Haemost 8(11):2450–2457CrossRefPubMed
16.
Zurück zum Zitat Salazar AJ et al (2017) Predictors of active cancer thromboembolic outcomes: mortality associated with calf deep vein thrombosis. Int Angiol 36(6):553–557 Salazar AJ et al (2017) Predictors of active cancer thromboembolic outcomes: mortality associated with calf deep vein thrombosis. Int Angiol 36(6):553–557
17.
Zurück zum Zitat Dentali F et al (2017) Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study. J Thromb Haemost 15(9):1757–1763CrossRefPubMed Dentali F et al (2017) Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study. J Thromb Haemost 15(9):1757–1763CrossRefPubMed
18.
Zurück zum Zitat Sgouros J, Maraveyas A (2008) Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer. Acta Oncol 47(3):337–346CrossRefPubMed Sgouros J, Maraveyas A (2008) Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer. Acta Oncol 47(3):337–346CrossRefPubMed
19.
Zurück zum Zitat Elewa H, Elrefai R, Barnes GD (2016) Cancer-associated venous thromboembolism. Curr Treatment Opt Cardiovasc Med 18(4):23CrossRef Elewa H, Elrefai R, Barnes GD (2016) Cancer-associated venous thromboembolism. Curr Treatment Opt Cardiovasc Med 18(4):23CrossRef
20.
Zurück zum Zitat Falz AS, Khan I, Beckman MG et al (2015) Characteristics and risk factors of cancer associated venous thromboembolism. Thromb Res 136(3):535–541CrossRef Falz AS, Khan I, Beckman MG et al (2015) Characteristics and risk factors of cancer associated venous thromboembolism. Thromb Res 136(3):535–541CrossRef
21.
Zurück zum Zitat Kline JA et al (2015) Emergency evaluation for pulmonary embol-ism, part 1: clinical factors that increase risk. J Emerg Med 49(1):104–117CrossRefPubMed Kline JA et al (2015) Emergency evaluation for pulmonary embol-ism, part 1: clinical factors that increase risk. J Emerg Med 49(1):104–117CrossRefPubMed
22.
Zurück zum Zitat Le Gal G et al (2006) Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 144(3):165–171CrossRefPubMed Le Gal G et al (2006) Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 144(3):165–171CrossRefPubMed
23.
Zurück zum Zitat Nolan L et al (2011) The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer. The Breast 20(2):151–154CrossRefPubMed Nolan L et al (2011) The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer. The Breast 20(2):151–154CrossRefPubMed
24.
Zurück zum Zitat Cavo M et al (2002) Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 100(6):2272–2273CrossRefPubMed Cavo M et al (2002) Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 100(6):2272–2273CrossRefPubMed
25.
Zurück zum Zitat Mukai M, Oka T (2018) Mechanism and management of cancer-associated thrombosis. J Cardiol 72:89–93CrossRefPubMed Mukai M, Oka T (2018) Mechanism and management of cancer-associated thrombosis. J Cardiol 72:89–93CrossRefPubMed
26.
Metadaten
Titel
Comparison and screening of different risk assessment models for deep vein thrombosis in patients with solid tumors
verfasst von
Meng-meng Wang
Xiao-juan Qin
Xiao-xiao He
Meng-jun Qiu
Gang Peng
Sheng-li Yang
Publikationsdatum
04.05.2019
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 2/2019
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-019-01840-x

Weitere Artikel der Ausgabe 2/2019

Journal of Thrombosis and Thrombolysis 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.